CryoPort (CYRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CryoPort

NasdaqCM•Industrials•Integrated Freight & Logistics

$15.27+0.13(0.01%)After hours

Market Cap

$846.43M

P/S

4.5x

P/B

1.7x

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

How this company scores

WeakMetricSide Score: 34/100

Grade capped at D — Interest coverage below 1× (-18.0x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (17/25); weakest: Growth (3/25).

Profitability8/25

Growth3/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayLow leverageImproving leverageNet cash position

Grade capped at D

Interest coverage below 1× (-18.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 4.9x5y range 4.9x – 7.0x

Currently near its 4-quarter median.

P/S · 4.5x5y range 1.4x – 14.3x

Currently above its 20-quarter median.

P/B · 1.7x5y range 0.7x – 4.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $846.43M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $186.45M
Q. Revenue: $48.97M
TTM EBITDA: $-11.56M
TTM Op. Income: $-37.33M
Q. Op. Income: $-10.04M
TTM Net Income: $-33.70M
Q. Net Income: $-8.26M
EPS: $-0.2
Shares Out.: $50.44M

$186.45M in TTM revenue declined 8.0% YoY, reaching $48.97M last quarter. TTM EBITDA of $-11.56M and TTM operating income of $-37.33M show growth is flowing through to the bottom line. However, net income is negative at $33.70M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 46.6%
EBITDA Margin: -7.0%
Op. Margin: -20.5%
Net Margin: -16.9%

Op. margin of -20.5% is up 0.7% YoY — cost efficiency is improving. Net margin at -16.9% and gross margin of 46.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 4.5x
P/B Ratio: 1.7x

P/S of 4.5x and P/B of 1.7x. Across the last 4 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $756.20M
Cash: $269.27M
Long-Term Debt: $985,000
Book Value: $490.70M
D/E Ratio: 0.0
Debt/EBITDA: N/A

With $756.20M in assets and $985,000 in long-term debt, D/E is 0.0and book value is $490.70M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.13M
TTM Free Cash Flow: $-20.03M
FCF Margin: -10.7%
FCF / Net Income: 0.6

TTM FCF of $-20.03M on $1.13M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.